S100A10, a novel biomarker in pancreatic ductal adenocarcinoma

Moamen Bydoun; Andra Sterea; Henry Liptay; Andrea Uzans; Weei Yuarn Huang; Gloria J. Rodrigues; Ian C.G. Weaver; Hong Gu; David M. Waisman

doi:10.1002/1878-0261.12356

S100A10, a novel biomarker in pancreatic ductal adenocarcinoma

Moamen Bydoun, Andra Sterea, Henry Liptay, Andrea Uzans, Weei Yuarn Huang, Gloria J. Rodrigues, Ian C.G. Weaver, Hong Gu, David M. Waisman

Medicine

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence-free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer.

Original language	English
Pages (from-to)	1895-1916
Number of pages	22
Journal	Molecular Oncology
Volume	12
Issue number	11
DOIs	https://doi.org/10.1002/1878-0261.12356
Publication status	Published - Nov 2018

Bibliographical note

Funding Information:
Support was provided by grant funding to DMW from the Canadian Institutes of Health Research (CIHR, MOP-123212). ICGW was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2013-4360204). MB is supported through the cancer research training program (CRTP) administered by the Beatrice Hunter Cancer Research Institute (BHCRI), Izaak Walton Killam Doctoral Scholarship, Nova Scotia Health Research Foundation (NSHRF), abd Nova Scotia Research Innovation Graduate Scholarship (NSRIGS). MB and AU were funded through a Dalhousie University Collaborative Grant.

Publisher Copyright:
© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

ASJC Scopus Subject Areas

Molecular Medicine
Genetics
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1878-0261.12356

Cite this

@article{d340fd8cf4b94d43b656deb1fb95d918,

title = "S100A10, a novel biomarker in pancreatic ductal adenocarcinoma",

abstract = "Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence-free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer.",

author = "Moamen Bydoun and Andra Sterea and Henry Liptay and Andrea Uzans and Huang, {Weei Yuarn} and Rodrigues, {Gloria J.} and Weaver, {Ian C.G.} and Hong Gu and Waisman, {David M.}",

note = "Funding Information: Support was provided by grant funding to DMW from the Canadian Institutes of Health Research (CIHR, MOP-123212). ICGW was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2013-4360204). MB is supported through the cancer research training program (CRTP) administered by the Beatrice Hunter Cancer Research Institute (BHCRI), Izaak Walton Killam Doctoral Scholarship, Nova Scotia Health Research Foundation (NSHRF), abd Nova Scotia Research Innovation Graduate Scholarship (NSRIGS). MB and AU were funded through a Dalhousie University Collaborative Grant. Publisher Copyright: {\textcopyright} 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.",

year = "2018",

month = nov,

doi = "10.1002/1878-0261.12356",

language = "English",

volume = "12",

pages = "1895--1916",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "11",

}

TY - JOUR

T1 - S100A10, a novel biomarker in pancreatic ductal adenocarcinoma

AU - Bydoun, Moamen

AU - Sterea, Andra

AU - Liptay, Henry

AU - Uzans, Andrea

AU - Huang, Weei Yuarn

AU - Rodrigues, Gloria J.

AU - Weaver, Ian C.G.

AU - Gu, Hong

AU - Waisman, David M.

N1 - Funding Information: Support was provided by grant funding to DMW from the Canadian Institutes of Health Research (CIHR, MOP-123212). ICGW was funded by the Natural Sciences and Engineering Research Council of Canada (NSERC, RGPIN-2013-4360204). MB is supported through the cancer research training program (CRTP) administered by the Beatrice Hunter Cancer Research Institute (BHCRI), Izaak Walton Killam Doctoral Scholarship, Nova Scotia Health Research Foundation (NSHRF), abd Nova Scotia Research Innovation Graduate Scholarship (NSRIGS). MB and AU were funded through a Dalhousie University Collaborative Grant. Publisher Copyright: © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

PY - 2018/11

Y1 - 2018/11

N2 - Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence-free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer.

AB - Pancreatic cancer is arguably the deadliest cancer type. The efficacy of current therapies is often hindered by the inability to predict patient outcome. As such, the development of tools for early detection and risk prediction is key for improving outcome and quality of life. Here, we introduce the plasminogen receptor S100A10 as a novel predictive biomarker and a driver of pancreatic tumor growth and invasion. We demonstrated that S100A10 mRNA and protein are overexpressed in human pancreatic tumors compared to normal ducts and nonductal stroma. S100A10 mRNA and methylation status were predictive of overall survival and recurrence-free survival across multiple patient cohorts. S100A10 expression was driven by promoter methylation and the oncogene KRAS. S100A10 knockdown reduced surface plasminogen activation, invasiveness, and in vivo growth of pancreatic cancer cell lines. These findings delineate the clinical and functional contribution of S100A10 as a biomarker in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85053692790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053692790&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12356

DO - 10.1002/1878-0261.12356

M3 - Article

C2 - 30009399

AN - SCOPUS:85053692790

SN - 1574-7891

VL - 12

SP - 1895

EP - 1916

JO - Molecular Oncology

JF - Molecular Oncology

IS - 11

ER -

S100A10, a novel biomarker in pancreatic ductal adenocarcinoma

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this